Ozawa Clare's Form 4 filing
Oyster Point Pharma, Inc. (OYST) · filed Oct 20, 2021
- Accession no.
- 0000899243-21-040771
- Filed
- Oct 20, 2021
- Trade date
- Oct 18, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $8.16M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ozawa ClareCIK 0001746742 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 18, 2021 | Common Stock | SSaleDisposed | −303,614 | $14.63 | −$4,441,872.82 | 1,057,976 | Indirect | |
| Oct 18, 2021 | Common Stock | SSaleDisposed | −1,912 | $14.63 | −$27,972.56 | 6,518 | Indirect | |
| Oct 18, 2021 | Common Stock | SSaleDisposed | −242,943 | $15.09 | −$3,666,009.87 | 815,033 | Indirect | |
| Oct 18, 2021 | Common Stock | SSaleDisposed | −1,531 | $15.09 | −$23,102.79 | 4,987 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.